Lake Street Capital Issues Positive Forecast for Cellebrite DI (NASDAQ:CLBT) Stock Price

Cellebrite DI (NASDAQ:CLBT) had its price objective boosted by research analysts at Lake Street Capital from $17.00 to $26.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s target price would indicate a potential upside of 27.45% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday. Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research note on Friday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $23.43.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT traded down $1.30 during trading on Friday, reaching $20.40. The company had a trading volume of 940,124 shares, compared to its average volume of 1,820,456. Cellebrite DI has a 52 week low of $9.96 and a 52 week high of $26.30. The stock has a market cap of $4.20 billion, a PE ratio of -13.19, a PEG ratio of 3.72 and a beta of 1.47. The business’s 50 day moving average price is $22.58 and its 200-day moving average price is $19.10.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Equities analysts anticipate that Cellebrite DI will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of CLBT. Quarry LP bought a new stake in Cellebrite DI in the third quarter valued at approximately $27,000. Advisors Asset Management Inc. increased its stake in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares in the last quarter. Pathway Financial Advisers LLC increased its stake in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares in the last quarter. NewEdge Advisors LLC increased its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after purchasing an additional 3,352 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Cellebrite DI in the fourth quarter valued at approximately $100,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.